ArticleJournal of thoracic disease2026
Burden of multidrug-resistant and extensively drug-resistant tuberculosis in China, India and Russia: estimates from the GBD 2023 study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB/XDR-TB) strains are complicating global tuberculosis (TB) control, with China, India, and Russia bearing the heaviest burdens. This study aimed to map their epidemiological profiles to guide targeted interventions. Methods: Epidemiological data were collected from the Global Burden of Disease Study (GBD) 2023. Joinpoint regression, decomposition, age-period-cohort, and autoregressive integrated moving average (ARIMA) analyses were performed. Results: China, India, and Russia ranked among the top three globally in the absolute number of MDR-TB/XDR-TB cases. Over the past 30 years, China had seen a significant decrease in the age-standardized rate of MDR-TB, contrasting with the rising trends in India and Russia, with epidemiological changes being the main driving factor. China had a significantly negative net drift value for XDR-TB mortality, indicating an overall decline across age groups over time, whereas India and Russia had significantly positive values, indicating an overall increase across age groups. In recent years, the burden of XDR-TB had decreased in China and Russia, while there had been no significant change in India. In all three countries, disease burden was higher in men than women, with significant differences in peak age. Predictions indicate rising XDR-TB prevalence in India and Russia, while China's indicators were expected to stabilize. Conclusions: MDR-TB/XDR-TB's epidemiological characteristics differ significantly among China, India, and Russia, necessitating the development of differentiated prevention and control strategies and strengthened joint efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.